Find a Viewpoint

Antimicrobial Viewpoints are articles in which experts in different areas of antimicrobial resistance share their knowledge and opinions about the current status and the future challenges of this field. You can read our editorial and ethics policies for these articles here

<br>Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them</br><em> – by Jack Stone and Maria Laura Ciusa</em>
5 August 2020

Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them – by Jack Stone and Maria Laura ...

more
<br>Getting the most out of antimicrobial surveillance</br><em> – by Mariana Castanheira</em>
28 May 2020

Getting the most out of antimicrobial surveillance – by Mariana Castanheira

more
<br>COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?</br><em> – by Stephan Harbarth</em>
13 May 2020

COVID-19 and antimicrobial resistance: Are there any unknowns that will become known? – by Stephan Harbarth

more
<br>COVID-19 and its impact on antimicrobial stewardship</br><em> – by Andrew Seaton</em>
30 April 2020

COVID-19 and its impact on antimicrobial stewardship – by Andrew Seaton

more
<br>The critical need for alternative approaches to address antibiotic treatment failure</br><em> – by Bob Hancock</em>
16 April 2020

The critical need for alternative approaches to address antibiotic treatment failure – by Bob Hancock

more
<br>COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever</br><em> – by Manica Balasegaram</em>
2 April 2020

COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever – by Manica Balasegaram

more
<br>The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation</br><em> – by Ryan Cirz and Kevin Krause</em>
17 March 2020

The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation – by Ryan Cirz and Kevin Krause

more
<br>Diagnostics to safeguard new and current antibiotics for gonorrhoea</br><em> – by Cassandra Kelly-Cirino and Cecilia Ferreyra</em>
22 January 2020

Diagnostics to safeguard new and current antibiotics for gonorrhoea – by Cassandra Kelly-Cirino and Cecilia Ferreyra

more
<br>On fireworks and finding ways to address drug-resistance in low- and middle-income countries</br><em> – by Ramanan Laxminarayan</em>
16 December 2019

On fireworks and finding ways to address drug-resistance in low- and middle-income countries – by Ramanan Laxminarayan

more
<br>Bringing antimicrobial research and development to Africa – the time is now</br><em> – by Greg Basarab and Kelly Chibale</em>
3 December 2019

Bringing antimicrobial research and development to Africa – the time is now – by Greg Basarab and Kelly Chibale

more
<br>Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why</br><em> – by Tim Jinks</em>
19 November 2019

Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why – by Tim Jinks

more
<br>A new cephalosporin has been approved</br><em> – by Ursula Theuretzbacher</em>
15 November 2019

A new cephalosporin has been approved – by Ursula Theuretzbacher

more
<br>Are new antibiotic combinations the solution to the AMR crisis?</br><em> – by Anthony Coates</em>
15 October 2019

Are new antibiotic combinations the solution to the AMR crisis? – by Anthony Coates

more
<br>Lessons from a recent outbreak of carbapenem-resistant <em>Klebsiella pneumoniae</em> in a neonatal unit</br><em> – by Adrie Bekker</em>
23 September 2019

Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit – by Adrie Bekker

more
<br>Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?</br><em> – by Colm Leonard & Tracy Parker</em>
2 September 2019

Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel? – by Colm Leonard & Tracy Parker

more
<br>Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool</br><em> – by Wes Kim & Katie Prosen</em>
27 June 2019

Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool – by Wes Kim & Katie Prosen

more
<br>How to steward new antibiotics into low- and middle-income countries (LMICs)?</br><em> – by Marc Mendelson & Adrian Brink</em>
27 March 2019

How to steward new antibiotics into low- and middle-income countries (LMICs)? – by Marc Mendelson & Adrian Brink

more
<br>The REPAIR Impact Fund: Reflections from the first year</br><em> – by Aleks Engel</em>
28 February 2019

The REPAIR Impact Fund: Reflections from the first year – by Aleks Engel

more
<br>Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance</br><em> – by Sarah Paulin and Peter Beyer</em>
25 February 2019

Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance – by ...

more
<br>Time to pull out all the stops in the fight against superbugs</br><em> – by Kevin Outterson</em>
13 February 2019

Time to pull out all the stops in the fight against superbugs – by Kevin Outterson

more
<br>Why we need to prioritize developing antibiotics for children</br><em> – by Manica Balasegaram</em>
24 January 2019

Why we need to prioritize developing antibiotics for children – by Manica Balasegaram

more
<br>Recent approvals – do they make a difference?</br><em> – by Ursula Theuretzbacher</em>
13 December 2018

Recent approvals – do they make a difference? – by Ursula Theuretzbacher

more
<br>More than one model to stimulate antimicrobial drug development</br><em> – by Jim O’Neill</em>
14 November 2018

More than one model to stimulate antimicrobial drug development – by Jim O’Neill

more

Share

FacebookTwitterLinkedInEmail
✕

Newsletter

Subscribe to our newsletter to stay up-to-date about our webinars, conferences and other activities.



View previous newsletters

Go to Top